Date (Month/Day/Year) Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Transaction (Month/Day/Year) Disposed Of (D) (Instr. 3, 4 and 5) Securities Demotivative (Nonth/Day/Year) Form: Direct (D) or Indirect (R) or (D) Form: Direct (D) or Indirect (R) or (Instr. 4) Indirect (D) or Indirect (R) or (Instr. 4) Indirect (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of, or Beneficially (Instr. 3) Price Form: Direct (R) or (D) or Indirect (R) or (Instr. 4) Form: Direct (R) or (R) or (R) or (R) Form: Direct (R) or (R) Indirect (R) or (R) 1. Title of Derivative Security (Instr. 3) 3. Transaction Or Exercise (Month/Day/Year) 3. Transaction (R) (Instr. 4) 3. Transaction (R) (R) 3. Transaction (R) (R) 3. Transaction (Month/Day/Year) 5. Number of Derivative Securities (Instr. 4) 6. Date Exercisable and Expiration Date (R) 7. Title and Amount of Securities Underlying (R) 8. Price of Derivative Security (Instr. 3) 9. Number of Derivative Security (Instr. 4) 10. Ownership Form: Direct (R) 11. Na of Indi Reported Following (R)	SEC For	rm 4																		
Check this box if no longer subject to section 1(b). STATE ENERT OF CHANGES IN DECRETIONAL CONTROL STATE Instruction 1(b). Estimate average burden tours per response: 0 1. Name and Address of Reporting Person" Harris Matthew Scott 2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. UTTE 201S 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Croup Filing (Check Applicable Line) 3. Date of Earliest Transaction (City) (Street) 2. Transaction (Month/Day/Year) 8. Securities Acquired, Disposed of, or Beneficially Owned 6. Individual or Joint/Croup Filing (Check Applicable Line) 1. Title of Security (Instr. 3) 2. Transaction (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Accounted, Line Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) 6. Ownership (Instr. 4) 6. Ownership (Instr. 4) 1.		FORM	UNITE														OMB	APPRO	VAL	
Harris Matthew Scott Altimmune, Inc. [ALT] (Check all applicable) Director 10% Owner (Last) (First) (Midde) Other (specify below) 01/30/2023 Chief Medical Officer (Street) 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable) Chief Medical Officer (Street) (Gitter 2018) 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable) (City) (State) (Zip) 2. Transaction Date 3. Transaction Date 3. Transaction (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable) 1. Title of Security (Instr. 3) 2. Transaction Date 3. Transaction Date 3. Transaction Date 3. Transaction (Month/Day/Year) 4. Securities Acquired (A) or Downed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Meaning (Instr. 4) 6. Ownership File (Month/Day/Year) 6. Securities Acquired (A) or Date 5. Amount of Securities (Instr. 3) 6. Ownership File (Month/Day/Year) 6. Securities Acquired (D) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities (Instr. 4) 6. Ownership File (Month/Day/Year) 6. Securities (Instr. 4)	Section 16. Form 4 or Form 5 obligations may continue. See				Filed pursuant to Section 16(a) of the Securities Exchance Act of 1934									_	HIP	Estim	OMB Number: 3235-0. Estimated average burden			
(Last) (First) (Middle) (C) ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S 3. Date of Earliest Transaction (Month/Day/Year) Chief Medical Officer (Street) (Street) (Gartrifter SBURG MD 20878 (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (e.g., puts, calls, warrants, options, convertible securities acquired (A) or (D) (Instr. 4) 5. Januart of (Instr. 4) 5. Amount of (Instr. 4) 5. Amount of (Instr. 4) 6. Ownership (Instr. 4) 1. Title of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 5. Amount of (Instr. 4) 5. Amount of (Instr. 4) 5. Amount of (Instr. 4) 6. Ownership (Instr. 4) 1. Title of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 5. Januart (Instr. 4) 8. Price of (Instr. 4) 9. Price of (Instr. 4) <td colspan="5"></td> <td colspan="9"></td> <td>(Che</td> <td colspan="4">(Check all applicable) Director 10% Owner</td> <td>wner</td>															(Che	(Check all applicable) Director 10% Owner				wner
(Street) GAITHERSBURG MD 20878 Line) Line) Image: Conversion of Derivative Securities Acquired, Disposed of, or Beneficially Owned (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned S. Amount of Disposed of (D) (Instr. 3, 4 and 5) S. Amount of Disposed of (D) (Instr. 3, 4 and 5) S. Securities Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction (Month/Day/Year) ZA. Deemed Execution Date, (Month/Day/Year) 3. Transaction (D) (Instr. 4) S. Amount of Disposed of (D) (Instr. 3, 4 and 5) S. Securities Beneficially Owned 1. Title of Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) 1. Title of Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) S. Amount of Securities Securities (I) (Instr. 4) S. Number of Or Exercise (Month/Day/Year) S. Number of Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g. or Disposed of (D) (Instr. 3 and 4) S. Number of Or Indirect (D) Owned (e.g. or Disposed of (D) (Instr. 5) S. Number of Individual Conversion (Instr. 4) 1. Title of Derivative Securities Acquired, Month/Day/Year) 3. Transaction (Code (Instr. 8) S. Number of Derivative Securities (I) (Instr. 3) S. Number of Indirect (D) Owned (I) (Instr. 5) S. Number of Indirect (D) Owneship Formacon (I) (Instr. 5) S. Number o	C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,															A below) below)				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially (Instr. 4) 5.	GAITHERSBURG MD 20878				4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 5. Amount of Securities Beneficially Owned Following Reported Transaction(S) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (D)	(City)	(S	,		-Doriv	ativo	Secu	ritios A	cauira	ad D	ien	o bosod	of or B	lon	oficially	/ Owned				
I. Title of Derivative Security (Instr. 3) 3. Transaction Date (Instr. 3) 3. Transaction Date (Month/Day/Year) 4. Transaction (Month/Day/Year) 5. Number of Derivative Securities (Month/Day/Year) 6. Date Exercise (Month/Day/Year) 7. Title and Amount of Securities (Month/Day/Year) 8. Price of Derivative Securities (Month/Day/Year) 10. Ownership Form: Direct (D) Ownership Security (Instr. 3), 4 and 5)	1. Title of Security (Instr. 3) Date			action	2A. Exe ar) if a	2A. Deemed Execution Date, if any		3. Transaction Code (Instr.		4. Securities Acquired (A)			I (A) or	or 5. Amount o 4 and 5) Securities Beneficially Owned Follo		Form (D) or	: Direct Indirect	Beneficial Ownership		
1. Title of Derivative Security (Instr. 3) 2. Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Derivative Security 5. Number of Derivative Security 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Acquired (A) or Disposed of (D) (Instr. Security 8. Price of Derivative Security 9. Number of Derivative Security 10. Ownership Form: (Instr. 4) 11. Nation Ownership (Instr. 4)										de V	'	Amount	(A) (D)) or)	Price					
1. Title of Derivative Security 2. Conversion (Instr. 3) 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Derivative Security 5. Number of Derivative Security 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security 8. Price of Derivative Security 9. Number of derivative Security 10. Ownership Form: Underlying Ownership Ownership Ownership (Instr. 3)																Owned				
Transaction(s) (Instr. 4)	Derivative Conversion Security or Exercise (Instr. 3) Price of Derivative		Date	Execution Date, Tr if any C		insactio	on De str. Se Ac or of	Derivative E Securities (I Acquired (A) or Disposed of (D) (Instr.		Expiration Date			of Securities Underlying Derivative Security (Instr. 3 and 4)			Derivative Security	derivativ Securitie Beneficia Owned Followin Reported Transact	e es ally g	Ownership Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)

Explanation of Responses:

\$12.88

(2)

01/30/2023

01/30/2023

1. Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value \$0.0001, when vested.

Code v

Α

Α

(A)

105,000

37,100

3. The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

(D) Exercisable

(1)

(3)

Expiration Date

01/30/2033

(3)

Title

Common Stock,

par value \$0.0001 Common

Stock.

par value \$0.0001

Remarks:

Stock Options

(option to buy)

Restricted

Stock

Units

Exhibit 24 - Power of Attorney

/s/ Richard Eisenstadt, as Attorney-in-Fact

Amount or

Number of Shares

105,000

37,100

\$0.00

\$0.00

** Signature of Reporting Person

02/01/2023 Date

105,000

37,100

D

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Richard Eisenstadt, Kent Tapper and Siavosh Salimi, signing singly, the undersigned's true and lawful attorney-in-fact to:

- execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Altimmune, Inc. (the "Company"),
 (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of February, 2022.

/s/ Matthew Scott Harris Signature

Matthew Scott Harris Print Name